International Myeloma Working Group diagnostic criteria for relapsed disease in multiple myeloma
Nonaggressive relapse . | ||
---|---|---|
Biochemical relapse . | Symptomatic relapse . | Aggressive relapse . |
Progression based on increase of M-protein | Slow inset of clinical symptoms and slowly increasing M-protein | Adverse cytogenetic abnormalities, eg, t(4;14), del(17p), ampl (1q21), hypodiploidy |
No associated symptoms or MM-related organ dysfunction | Progressive disease with prominent symptoms and/or significant organ compromise | High β2M (>5.5 mg/L) or low albumin (<3.5 g/dL) |
Presence of extramedullary disease | ||
High LDH | ||
Short duration of response or progression while on therapy | ||
Aggressive clinical presentation including: | ||
• Rapid onset of symptoms | ||
• Extensive disease on laboratory, radiography, or pathology findings | ||
• Disease-associated organ impairment | ||
Circulating plasma cells | ||
ISS stage II/III at relapse | ||
Isotype transformation (light chain escape, hyposecretory disease) |
Nonaggressive relapse . | ||
---|---|---|
Biochemical relapse . | Symptomatic relapse . | Aggressive relapse . |
Progression based on increase of M-protein | Slow inset of clinical symptoms and slowly increasing M-protein | Adverse cytogenetic abnormalities, eg, t(4;14), del(17p), ampl (1q21), hypodiploidy |
No associated symptoms or MM-related organ dysfunction | Progressive disease with prominent symptoms and/or significant organ compromise | High β2M (>5.5 mg/L) or low albumin (<3.5 g/dL) |
Presence of extramedullary disease | ||
High LDH | ||
Short duration of response or progression while on therapy | ||
Aggressive clinical presentation including: | ||
• Rapid onset of symptoms | ||
• Extensive disease on laboratory, radiography, or pathology findings | ||
• Disease-associated organ impairment | ||
Circulating plasma cells | ||
ISS stage II/III at relapse | ||
Isotype transformation (light chain escape, hyposecretory disease) |
LDH, lactate dehydrogenase.